Lilly's lipoprotein-blocking heart med posts midstage win, turning up heat on potential AZ showdown

A little more than a month after AstraZeneca jumped into the fray with the purchase of a rival heart drug candidate, Eli Lilly is turning up the heat on the drugmakers’ potential lipoprotein showdown.